Anti-PD-1therapy Combined With Thermal Ablation for Advanced HCC
Status:
Completed
Trial end date:
2019-07-31
Target enrollment:
Participant gender:
Summary
The inhibition of programmed cell death protein 1 (PD-1) has shown promising antitumor
activity in advanced hepatocellular carcinoma (HCC). Unfortunately, less than 20% of HCC have
response. The effect of PD-1 blockade and incomplete thermal ablation in patients with
advanced HCC is not yet clearly understood. This study aimed to analyze outcomes of advanced
HCC treated with anti PD-1 inhibitors in combination with incomplete thermal ablation.